MedTrace Logo

Trial of Low-Dose Naltrexone for Children With Pervasive Developmental Disorder (PDD)

NCT00318162 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2006-05-03

No results posted yet for this study

Summary

This study will examine the effects of low-dose naltrexone (LDN) on children with autistic spectrum disorders. The investigators hope to show a positive effect on social functioning and language.

Conditions

  • Pervasive Developmental Disorder

Interventions

DRUG

low dose naltrexone

Sponsors & Collaborators

  • Jerusalem Institute for Child Development

    collaborator UNKNOWN

  • Hadassah Medical Organization

    lead OTHER

Principal Investigators

  • David S Wilensky, MD · Jerusalem Institute for Child Development

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
3 Years
Max Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00318162 on ClinicalTrials.gov